Assessment of estrogenic, mutagenic and antimutagenic activity of nemorosone

Detalhes bibliográficos
Autor(a) principal: Camargo,Mariana S.
Data de Publicação: 2011
Outros Autores: Varela,Soraya D., Oliveira,Ana Paula S. de, Resende,Flávia Ap., Cuesta-Rubio,Osmay, Vilegas,Wagner, Varanda,Eliana A.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Revista Brasileira de Farmacognosia (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0102-695X2011000500021
Resumo: Currently, a wide range of research involving natural products is focused on the discovery of new drugs in many different therapeutic areas. A great number of the synthetic compounds on the market were derived from natural products, especially plants. Nemorosone is the major constituent of the floral resin of Clusia rosea Jacq., Clusiaceae, and in Cuban propolis. In vitro studies have shown cytotoxic activity in this substance against various tumor cell lines, including those resistant to various cytotoxic drugs, whereas it has low cytotoxicity to non-tumoral cells. Therefore, in order to characterize the biological activity of nemorosone, a substance with potential antitumor activity, and in view of preclinical testing of the toxicity of drug candidate compounds, the main aim of this study was to determine the mutagenic and antimutagenic activity of nemorosone by the Ames test, using the strains TA97a, TA98, TA100 and TA102 of Salmonella typhimurium. Secondly, to characterize the estrogenic activity in an experimental recombinant yeast model (Recombinant Yeast Assay) mutagenic activity was observed at in any of the concentrations in any of the test strains. To evaluate the antimutagenic potential, direct and indirect mutagenic agents were used: 4 nitro-o-phenylenediamine (NPD), mitomycin C (MMC) and aflatoxin B1 (AFL). Nemorosone showed moderate antimutagenic activity (inhibition level 31%), in strain TA100 in the presence of AFL, and strong antimutagenic activity in TA102 against MMC (inhibition level 53%). Estrogenic activity was observed, with an EEq of 0.41±0.16 nM at various tested concentrations.
id SBFGNOSIA-1_1056f331be4fb7d01aa382681b7ffd27
oai_identifier_str oai:scielo:S0102-695X2011000500021
network_acronym_str SBFGNOSIA-1
network_name_str Revista Brasileira de Farmacognosia (Online)
repository_id_str
spelling Assessment of estrogenic, mutagenic and antimutagenic activity of nemorosoneAmes testantimutagenic activityestrogenic activitynemorosoneCurrently, a wide range of research involving natural products is focused on the discovery of new drugs in many different therapeutic areas. A great number of the synthetic compounds on the market were derived from natural products, especially plants. Nemorosone is the major constituent of the floral resin of Clusia rosea Jacq., Clusiaceae, and in Cuban propolis. In vitro studies have shown cytotoxic activity in this substance against various tumor cell lines, including those resistant to various cytotoxic drugs, whereas it has low cytotoxicity to non-tumoral cells. Therefore, in order to characterize the biological activity of nemorosone, a substance with potential antitumor activity, and in view of preclinical testing of the toxicity of drug candidate compounds, the main aim of this study was to determine the mutagenic and antimutagenic activity of nemorosone by the Ames test, using the strains TA97a, TA98, TA100 and TA102 of Salmonella typhimurium. Secondly, to characterize the estrogenic activity in an experimental recombinant yeast model (Recombinant Yeast Assay) mutagenic activity was observed at in any of the concentrations in any of the test strains. To evaluate the antimutagenic potential, direct and indirect mutagenic agents were used: 4 nitro-o-phenylenediamine (NPD), mitomycin C (MMC) and aflatoxin B1 (AFL). Nemorosone showed moderate antimutagenic activity (inhibition level 31%), in strain TA100 in the presence of AFL, and strong antimutagenic activity in TA102 against MMC (inhibition level 53%). Estrogenic activity was observed, with an EEq of 0.41±0.16 nM at various tested concentrations.Sociedade Brasileira de Farmacognosia2011-10-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0102-695X2011000500021Revista Brasileira de Farmacognosia v.21 n.5 2011reponame:Revista Brasileira de Farmacognosia (Online)instname:Sociedade Brasileira de Farmacognosia (SBFgnosia)instacron:SBFGNOSIA10.1590/S0102-695X2011005000148info:eu-repo/semantics/openAccessCamargo,Mariana S.Varela,Soraya D.Oliveira,Ana Paula S. deResende,Flávia Ap.Cuesta-Rubio,OsmayVilegas,WagnerVaranda,Eliana A.eng2011-09-23T00:00:00Zoai:scielo:S0102-695X2011000500021Revistahttp://www.sbfgnosia.org.br/revista/https://old.scielo.br/oai/scielo-oai.phprbgnosia@ltf.ufpb.br1981-528X0102-695Xopendoar:2011-09-23T00:00Revista Brasileira de Farmacognosia (Online) - Sociedade Brasileira de Farmacognosia (SBFgnosia)false
dc.title.none.fl_str_mv Assessment of estrogenic, mutagenic and antimutagenic activity of nemorosone
title Assessment of estrogenic, mutagenic and antimutagenic activity of nemorosone
spellingShingle Assessment of estrogenic, mutagenic and antimutagenic activity of nemorosone
Camargo,Mariana S.
Ames test
antimutagenic activity
estrogenic activity
nemorosone
title_short Assessment of estrogenic, mutagenic and antimutagenic activity of nemorosone
title_full Assessment of estrogenic, mutagenic and antimutagenic activity of nemorosone
title_fullStr Assessment of estrogenic, mutagenic and antimutagenic activity of nemorosone
title_full_unstemmed Assessment of estrogenic, mutagenic and antimutagenic activity of nemorosone
title_sort Assessment of estrogenic, mutagenic and antimutagenic activity of nemorosone
author Camargo,Mariana S.
author_facet Camargo,Mariana S.
Varela,Soraya D.
Oliveira,Ana Paula S. de
Resende,Flávia Ap.
Cuesta-Rubio,Osmay
Vilegas,Wagner
Varanda,Eliana A.
author_role author
author2 Varela,Soraya D.
Oliveira,Ana Paula S. de
Resende,Flávia Ap.
Cuesta-Rubio,Osmay
Vilegas,Wagner
Varanda,Eliana A.
author2_role author
author
author
author
author
author
dc.contributor.author.fl_str_mv Camargo,Mariana S.
Varela,Soraya D.
Oliveira,Ana Paula S. de
Resende,Flávia Ap.
Cuesta-Rubio,Osmay
Vilegas,Wagner
Varanda,Eliana A.
dc.subject.por.fl_str_mv Ames test
antimutagenic activity
estrogenic activity
nemorosone
topic Ames test
antimutagenic activity
estrogenic activity
nemorosone
description Currently, a wide range of research involving natural products is focused on the discovery of new drugs in many different therapeutic areas. A great number of the synthetic compounds on the market were derived from natural products, especially plants. Nemorosone is the major constituent of the floral resin of Clusia rosea Jacq., Clusiaceae, and in Cuban propolis. In vitro studies have shown cytotoxic activity in this substance against various tumor cell lines, including those resistant to various cytotoxic drugs, whereas it has low cytotoxicity to non-tumoral cells. Therefore, in order to characterize the biological activity of nemorosone, a substance with potential antitumor activity, and in view of preclinical testing of the toxicity of drug candidate compounds, the main aim of this study was to determine the mutagenic and antimutagenic activity of nemorosone by the Ames test, using the strains TA97a, TA98, TA100 and TA102 of Salmonella typhimurium. Secondly, to characterize the estrogenic activity in an experimental recombinant yeast model (Recombinant Yeast Assay) mutagenic activity was observed at in any of the concentrations in any of the test strains. To evaluate the antimutagenic potential, direct and indirect mutagenic agents were used: 4 nitro-o-phenylenediamine (NPD), mitomycin C (MMC) and aflatoxin B1 (AFL). Nemorosone showed moderate antimutagenic activity (inhibition level 31%), in strain TA100 in the presence of AFL, and strong antimutagenic activity in TA102 against MMC (inhibition level 53%). Estrogenic activity was observed, with an EEq of 0.41±0.16 nM at various tested concentrations.
publishDate 2011
dc.date.none.fl_str_mv 2011-10-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0102-695X2011000500021
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0102-695X2011000500021
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/S0102-695X2011005000148
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Brasileira de Farmacognosia
publisher.none.fl_str_mv Sociedade Brasileira de Farmacognosia
dc.source.none.fl_str_mv Revista Brasileira de Farmacognosia v.21 n.5 2011
reponame:Revista Brasileira de Farmacognosia (Online)
instname:Sociedade Brasileira de Farmacognosia (SBFgnosia)
instacron:SBFGNOSIA
instname_str Sociedade Brasileira de Farmacognosia (SBFgnosia)
instacron_str SBFGNOSIA
institution SBFGNOSIA
reponame_str Revista Brasileira de Farmacognosia (Online)
collection Revista Brasileira de Farmacognosia (Online)
repository.name.fl_str_mv Revista Brasileira de Farmacognosia (Online) - Sociedade Brasileira de Farmacognosia (SBFgnosia)
repository.mail.fl_str_mv rbgnosia@ltf.ufpb.br
_version_ 1752122466150383616